Year-end Sale % OFF 
Abstract
A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core–shell structured hemoglobin-albumin cluster designated as “HemoAct”, is an O2-carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.
Highlights
IntroductionSufficient blood might not be available in the event of a widespread disaster
To evaluate the preclinical safety of the HemoAct solution as an red blood cell (RBC) substitute, we examined the blood compatibility, hemodynamic response, and pharmacokinetic property of this new O2-carrier
These results indicate that HemoAct has good compatibility with whole blood
Summary
Sufficient blood might not be available in the event of a widespread disaster Another problem is that Japan’s declining birthrate and aging society make it difficult to maintain a stable blood transfusion system. A blood substitute, in particular an RBC substitute, is needed (i) which can be stored for long period, (ii) which presents no risk of virus infection, and (iii) which is useful for anyone irrespective of blood type. Such an artificial O2-carrier is required as a primary measure for crisis management, and is required as a medical measure to supplement blood transfusion treatment. To evaluate the preclinical safety of the HemoAct solution as an RBC substitute, we examined the blood compatibility, hemodynamic response, and pharmacokinetic property of this new O2-carrier
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
